On this page
- Long-lasting lactation inhibitor
- Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death
Forms and strengths
- 0.5 mg scored tablet
Dosage and duration
- 1 mg single dose on the first day post-partum
- 0.25 mg every 12 hours for 2 days
Contra-indications, adverse effects, precautions
- Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis.
- May cause: hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, hallu cinations.
- Do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine (risk of vasoconstriction and hypertensive crisis), and macrolides (effect of cabergoline increased).
- Pregnancy: CONTRA-INDICATED
- The use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously.
- Cabergoline is not included in the WHO list of essential medicines.
- Cabergoline is a dopamine agonist also used in the treatment of Parkinson’s disease.
- Below 25 °C